The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines
Open Access
- 19 June 2020
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 38 (34), 5556-5561
- https://doi.org/10.1016/j.vaccine.2020.06.017
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- The COVID-19 vaccine development landscapeNature Reviews Drug Discovery, 2020
- A Comparison of Plasmid DNA and mRNA as Vaccine TechnologiesVaccines, 2019
- rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessmentVaccine: X, 2019
- mRNA vaccines — a new era in vaccinologyNature Reviews Drug Discovery, 2018
- Mechanism of action of mRNA-based vaccinesExpert Review of Vaccines, 2017
- Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessmentVaccine, 2016
- Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk/benefit assessmentVaccine, 2014
- The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)Vaccine, 2014
- Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studiesVaccine, 2009
- The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)Vaccine, 2002